Compare VET & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VET | MPLT |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2004 | 2025 |
| Metric | VET | MPLT |
|---|---|---|
| Price | $11.85 | $11.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $15.00 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 1.4M | 1.3M |
| Earning Date | 05-06-2026 | 05-28-2026 |
| Dividend Yield | ★ 2.84% | N/A |
| EPS Growth | N/A | ★ 82.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.07 | N/A |
| Revenue Next Year | $3.40 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.00 | $9.10 |
| 52 Week High | $14.82 | $40.43 |
| Indicator | VET | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 59.79 | 28.31 |
| Support Level | $11.14 | $10.83 |
| Resistance Level | $11.93 | $20.73 |
| Average True Range (ATR) | 0.34 | 1.29 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 78.26 | 12.02 |
Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, and development of liquids-rich natural gas in Canada and conventional natural gas in Europe while optimizing low-decline oil assets. Its operating segments are: Canada, France, Netherlands, Germany, Ireland, Australia, and CEE, each representing the oil and gas exploration operations at its assets located in these regions. The company mainly derives revenue from the production and sale of petroleum and natural gas. The majority of its revenue is generated from Canada, where the company's operations are mainly focused on the Deep Basin trend in the West Pembina region of Alberta and on the Mica property.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.